Possible future therapeutics for Behçet’s syndrome

Bibliography

• BEHÇET H: Überrezidivierende aphthöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschrift (1937) 105:1152-1157.
   Google Scholar
• SHIMIZU T, EHRLICH GE, INABA G et al.: Behçet disease (Behçet syndrome). Semin. Arthritis Rheum. (1979) 8:223-260.
   Google Scholar
• SAKANE T, TAKENO M, NOBORU S et al.: Behçet’s disease. N. Engl. J. Med. (1999) 341:1284-1291.
   Google Scholar
• INTERNATIONAL STUDY GROUP FOR BEHÇET’S DISEASE: Criteria for diagnosis of Behçet’s disease. Lancet (1990) 335:1078-1080.
   Google Scholar
• GUL A: Behçet’s syndrome: an update on the pathogenesis. Clin. Exp. Rheumatol. (2001) 19(5 Suppl. 24):S6-S12.
   Google Scholar
• ZIERHUT M, MIZUKI N, OHNO S et al.: Immunology and functional genomics of Behçet’s disease. Cell Mol. Life Sci. (2003) 60:1903-1922.
   Google Scholar
• DIRESKENELI H: Behçet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann. Rheum. Dis. (2001) 60:996-1002.
   Google Scholar
• ARAYSSI T, HAMDAN A: New insights into the pathogenesis and therapy of Behçet's disease. Curr. Opin. Pharmacol. (2004) 4:183-188.
   Google Scholar
• HASAN A, FORTUNE F, WILSON A et al.: Role of γδ T cells in pathogenesis and diagnosis of Behçet's disease. Lancet (1996) 347:789-794.
   PubMed Web of Science ®Google Scholar
• AL-OTAIBI LM, PORTER SR, POATE TW: Behçet's disease: a review. J. Dent. Res. (2005) 84:209-222.
   Google Scholar
• KAKLAMANI VG, VAIOPOULOS G, KAKLAMANIS PG: Behçet’s syndrome. Semin. Arthritis Rheum. (1998) 27:197-217.
   Google Scholar
• YAZICI H: Behçet’s syndrome: where do we stand? Am. J. Med. (2002) 112:75-76.
   Google Scholar
• NUSSENBLATT RB: Bench to bedside: new approaches to the immunotherapy of uveitic disease. Int. Rev. Immunol. (2002) 21:273-289.
   Google Scholar
• SAENZ A, AUSEJO M, SHEA B, WELLS G, WELCH V, TUGWELL P: Pharmacotherapy for Behçet’s syndrome. Cochrane Database Syst. Rev. (2000):CD001084.
   Google Scholar
• KOTTER I, GUNAYDIN I, ZIERHUT M, STUBIGER N: The use of IFN-α in Behcet disease: review of the literature. Semin. Arthritis Rheum. (2004) 33:320-335.
   Google Scholar
• ESTRACH C, MPOFU S, MOOTS RJ: Behcet's syndrome: response to infliximab after failure of etanercept. Rheumatology (2002) 41:1213-1214.
   Google Scholar
• ANDO K, FUJINO Y, HIJIKATA K, IZAWA Y, MASUDA K: Epidemiological features and visual prognosis of Behçet’s disease. Jpn J. Ophthalmol (1999) 43:312-317.
   Google Scholar
• NOMURA E, IZUMI Y, YAMASHITA H et al.: Magnetic resonance imaging of brainstem lesions in a case of neuro-Behçet disease. No To Shinkei (1997) 49:273-276.
   Google Scholar
• KOTAKE S, HIGASHI K, YOSHIKAWA K, SASAMOTO Y, OKAMOTO T, MATSUDA H: CNS symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology (1999) 106:586-589.
   PubMed Web of Science ®Google Scholar
• SAKANE T, TAKENO M: Novel approaches to Behçet’s disease. Expert Opin. Investig. Drugs (2000) 9:1993-2005.
   Google Scholar
• EVEREKLIOGLU C: Current concepts in the etiology and treatment of Behçet disease. Surv. Ophthalmol. (2005) 50:297-350.
   Google Scholar
• LENSCHOW DJ, WALUNAS TL, BLUESTONE JA: CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. (1996) 14:233-258.
   Google Scholar
• ERBE DV, WANG S, XING Y, TOBIN JF: Small molecule ligands define a binding site on the immune regulatory protein B7.1. J. Biol. Chem. (2002) 277:7363-7368.
   Google Scholar
• SAVINI L, MASSARELLI P, NENCINI C et al.: High affinity central benzodiazepine receptor ligands: synthesis and structure–activity relationship studies of a new series of pyrazolo[4,3-c]quinolin- 3-ones. Bioorg. Med. Chem. (1998) 6:389-399.
   Google Scholar
• NEGISHI M, SUGIMOTO Y, ICHIKAWA A: Prostaglandin E receptors. J. Lipid Mediat. Cell Signal (1995) 12:379-391.
   Google Scholar
• KRAPPMANN D, PATKE A, HEISSMEYER V, SCHEIDEREIT C: B-cell receptor- and phorbol ester-induced NF-κB and c-Jun N-terminal kinase activation in B-cells requires novel protein kinase C's. Mol. Cell Biol. (2001) 21:6640-6650.
   Google Scholar
• BOLEN JB, BRUGGE JS: Leukocyte protein tyrosine kinases: potential targets for drug discovery. Annu. Rev. Immunol. (1997) 15:371-404.
   Google Scholar
• SORIANO P, MONTGOMERY C, GESKE R, BRADLEY A: Targeted disruption of the c-Src proto-oncogene leads to osteopetrosis in mice. Cell. (1991) 64:693-702.
   PubMed Web of Science ®Google Scholar
• ANDERSON SJ, LEVIN SD, PERLMUTTER RM: Involvement of the protein tyrosine kinase p56lck in T cell signaling and thymocyte development. Adv. Immunol. (1994) 56:151-178.
   Google Scholar
• SNOW RJ, CARDOZO MG, MORWICK TM et al.: Discovery of 2-phenylamino-imidazo[4,5-h]isoquinolin-9-ones: a new class of inhibitors of Lck kinase. J. Med. Chem. (2002) 45:3394-3405.
   Google Scholar
• BURCHAT AF, CALDERWOOD DJ, FRIEDMAN MM et al.: Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck – a selectivity insight. Bioorg. Med. Chem. Lett. (2002) 12:1687-1690.
   Google Scholar
• ALTMANN E, MISSBACH M, GREEN J, SUSA M, WAGENKNECHT HA, WIDLER L: 7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d]- pyrimidines – potent inhibitors of the tyrosine kinase c-Src. Bioorg. Med. Chem. Lett. (2001) 11:853-856.
   Google Scholar
• WANG YD, MILLER K, BOSCHELLI DH et al.: Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorg. Med. Chem. Lett. (2000) 10:2477-2480.
   Google Scholar
• CHEN P, IWANOWICZ EJ, NORRIS D et al.: Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency. Bioorg. Med. Chem. Lett. (2002) 12:3153-3156.
   Google Scholar
• BODMER JL, SCHNEIDER P, TSCHOPP J: The molecular architecture of the TNF superfamily. Trends Biochem. Sci. (2002) 27:19-26.
   PubMed Web of Science ®Google Scholar
• CHAN FK, CHUN HJ, ZHENG L, SIEGEL RM, BUI KL, LENARDO MJ: A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science (2000) 288:2351-2354.
   PubMed Web of Science ®Google Scholar
• DUPUIS DS, PEREZ M, HALAZY S, COLPAERT FC, PAUWELS PJ: Magnitude of 5-HT1B and 5-HT1A receptor activation in guinea-pig and rat brain: evidence from sumatriptan dimer-mediated [35S]GTPγS binding responses. Brain Res. Mol. Brain Res. (1999) 6;67(1):107-123.
   Google Scholar